Anthracycline-related cardiotoxicity in childhood cancer survivors

Current Opinion in Cardiology

Volumn 29, Issue 1, 2014, Pages 103-112

  Lipshultz, Steven E ^a,b,c   Karnik, Ruchika ^b   Sambatakos, Peter ^b   Franco, Vivian I ^b   Ross, Samuel W ^b   Miller, Tracie L ^b,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami Jackson Memorial Medical Center   (United States)

Author keywords

anthracyclines; cardiotoxicity; childhood cancer

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; GROWTH HORMONE; IDARUBICIN; MITOXANTRONE; RAZOXANE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SURVIVOR; CARDIOTOXICITY; CELL MEMBRANE; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CONTINUOUS INFUSION; DNA DAMAGE; DNA REPLICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HEART ARRHYTHMIA; HEART FAILURE; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HOSPITALIZATION; HUMAN; LIPID PEROXIDATION; LIPOSOMAL DELIVERY; LYMPHOMA; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICARDITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RNA TRANSCRIPTION; SIDE EFFECT; SOLID TUMOR; SUBSTITUTION THERAPY; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; CHILD; DISEASE PROGRESSION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN GROWTH HORMONE; HUMANS; NEOPLASMS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84890434161     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000034     Document Type: Review

References (96)

1. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24:320-334.
2. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
3. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94:525-533.
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
5. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2008; 100:1368-1379.
6. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: B4606.
7. Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among fiveyear survivors of cancer in childhood and adolescence: A population-based study in the Nordic countries. J Clin Oncol 2001; 19:3173-3181.
8. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in longterm overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28:1308-1315.
9. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: Beginning with the end in mind. J Clin Oncol 2010; 28:1276-1281.
10. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010; 304:172-179.
11. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324:808-815.
12. Levitt G, Anazodo A, Burch M, Bunch K. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need Eur J Cancer 2009; 45:3027-3034.
13. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727-741.
14. Chu E, Satorelli AC. Cancer chemotherapy. In: Basic and clinical pharmocology. 9th ed. New York: McGraw-Hill; 2003. pp. 898-930.
15. Lipshultz SE, Scully RE, Smith HM. Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia [abstract]. In: 5th World Congress of Pediatric Cardiology and Cardiac Surgery; 2009; Cairns, Australia.
16. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection Prog Cardiovasc Dis 2010; 53:105-113.
17. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990; 4:3076-3086.
18. Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007; 8:1039-1058.
19. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 2000; 71:436-444.
20. Lebrecht D, Setzer B, Ketelsen UP, et al. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003; 108:2423-2429.
21. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008; 26:3777-3784.
22. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229.
23. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004; 18:664-675.
24. Mihm MJ, Bauer JA. Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase. Biochimie 2002; 84:1013-1019.
25. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61:154-171.
26. Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998; 27: 53-68.
27. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17:2237-2243.
28. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracyclineinduced myocardial damage: A review of the most promising strategies. Br J Haematol 2005; 131:561-578.
29. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anticancer anthracycline drugs. Biochem Biophys Res Commun 2009; 378:450-455.
30. Thompson KL, Rosenzweig BA, Zhang J, et al. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 2010; 66:303-314.
31. Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 2011; 32:342-353.
32. Ito H, Miller SC, Billingham ME, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 1990; 87:4275-4279.
33. Jeyaseelan R, Poizat C,WuHY,Kedes L. Molecularmechanisms of doxorubicininduced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 1997; 272:5828-5832.
34. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004; 279:8290-8299.
35. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventive medicine. Mol Interv 2005; 5:163-171.
36. Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7:114-121.
37. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010; 121:276-292.
38. Jurcut R, Wildiers H, Ganame J, et al. Detection and monitoring of cardiotoxicity: What does modern cardiology offer Support Care Cancer 2008; 16:437-445.
39. Lowis S, Lewis I, Elsworth A, et al. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 2006; 95:571-580.
40. Takahashi S, Denvir MA, Harder L, et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2 release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae. Jpn J Pharmacol 1998; 76:405-413.
41. Calderone A, de Champlain J, Rouleau JL. Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J Mol Cell Cardiol 1991; 23:333-342.
42. Diamond M, Franco V. Preventing and treating anthracycline-related cardiotoxicity in survivors of childhood cancer. Curr Cancer Ther Rev 2012; 8:141-151.
43. Van Der Pal HJ, Van Dalen EC, Van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012; 30:1429-1437.
44. Kurt BA, Nolan VG, Ness KK, et al. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer 2012; 59:126-132. This is the first study to describe hospitalization rates among survivors of childhood cancer compared with the US population. Survivor hospitalization rates were 1.6 times the US population; however, additional studies are needed to quantify the healthcare utilization and economic impact of treatment-related complications.
45. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes. J Clin Oncol 2012; 30:1042-1049.
46. Lipshultz S, Messiah S, Miller T. Pediatric metabolic syndrome. Berlin: Springer; 2012. This is the first book on this emerging late effect in survivors of childhood cancer.
47. Apovian CM, Gokce N. Obesity and cardiovascular disease. Circulation 2012; 125:1178-1182.
48. Herouvi D, Karanasios E, Karayianni C, Karavanaki K. Cardiovascular disease in childhood: The role of obesity. Eur J Pediatr 2013; 172:721-732.
49. Steinberger J, Sinaiko AR, Kelly AS, et al. Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 2012; 160:494-499. This study describes the occurrence of cardiovascular risk factors in childhood cancer survivors before reaching adulthood. Young childhood cancer survivors have worse cardiovascular risk profiles than their sibling controls, which may contribute to their risk of early cardiovascular morbidity and mortality.
50. Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012; 30:1050-1057. This study demonstrates that childhood cancer survivors, regardless of whether they received cardiotoxic treatments or not, were at increased risk of cardiotoxicity. This observation highlights the importance of including cardiovascular concerns as part of general survivorship guidelines.
51. Oeffinger KC, Adams-Huet B, Victor RG, et al. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27:3698-3704.
52. Gurney JG, Ness KK, Sibley SD, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107:1303-1312.
53. Zerra P, Cochran TR, Franco VI, Lipshultz SE. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opin Pharmacother 2013; 14:1497-1513.
54. Lipshultz SE, Lipsitz SR, Kutok J, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013; 119:3555-3562. This study demonstrates that doxorubicin-treated survivors of childhood high-risk ALL who were heterozygous for the C282Y allele, one of the most commonly associated mutations in HFE, had a nine-fold increased risk of myocardial injury, compared with noncarriers. Screening for HFE mutations might identify those at higher risk for doxorubicin-associated cardiotoxicity, and inform treatment decisions.
55. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:545-550.
56. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-2636.
57. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133-139.
58. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 2002; 20:1677-1682.
59. Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: Long-term cardiac outcomes. Pediatrics 2012; 130:1003-1011. This is the first randomized-controlled trial in survivors of childhood high-risk ALL to demonstrate that continuous-infusion doxorubicin provides no long-term cardioprotection or improvement in ALL event-free survival. These findings suggest that the use of continuous anthracycline infusion provides no benefit over bolusinfusion, hence should be minimized or eliminated.
60. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988; 6:679-688.
61. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988; 6:976-982.
62. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 5:CD005006.
63. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058-1067.
64. Meinardi MT, Van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19:2746-2753.
65. Cowan JD, Neidhart J, McClure S, et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst 1991; 83:1077-1084.
66. Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22:663-669.
67. Leonard RC, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet). Breast 2009; 18:218-224.
68. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11:1029-1033.
69. Sieswerda E, Kremer LC, Caron HN, Van Dalen EC. The use of liposomal anthracycline analogues for childhood malignancies: A systematic review. Eur J Cancer 2011; 47:2000-2008.
70. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.
71. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-961. This is the first randomized clinical trial to demonstrate the long-term cardioprotection of dexrazoxane without compromising oncological efficacy in doxorubicintreated children with high-risk ALL. The article highlights the importance of administering dexrazoxane before each dose of doxorubicin during the first 90 days of therapy.
72. Lipincyzk TM, Lipshultz SE. Cardioprotective effects of dexrazoxane in children with acute lymphoblastic leukemia treated with doxorubicin: An overview. Am J Oncol Rev 2005; 4:103-116.
73. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase II beta mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007; 67:8839-8846.
74. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; 6:CD003917.
75. Herman EH, Knapton AD, Zhang J, et al. Gender is a factor that can impact the severity of doxorubicin (DXR) toxicity in spontaneously hypertensive rats (SHR). The Journal of the Federation of American Societies for Experimental Biology 2008; 22:719-726.
76. Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: A Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009; 64:243-251.
77. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988; 48:3634-3640.
78. Capizzi RL, Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: Clinical experiences. Eur J Cancer 1995; 31 (A Suppl 1):S8-S13.
79. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, et al. Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs 2004; 15:169-178.
80. Herman EH, Zhang J, Chadwick DP, Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 2000; 45:329-334.
81. De Flora S, Bennicelli C, Serra D, et al. Role of glutathione and N-acetylcysteine as inhibitors of mutagenesis and carcinogenesis. In: Friedman M, editor. Absorption and utilization of amino acids, Vol. Boca Raton: CRC Press; 1989. pp. 19-54.
82. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10 (1 Suppl 1):53-55.
83. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 (Suppl F):38-42.
84. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicininduced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004; 37:837-846.
85. Matsui H, Morishima I, Numaguchi Y, et al. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65:1265-1274.
86. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517-4522.
87. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: A multiinstitutional experience. J Heart Lung Transplant 1999; 18:269-274.
88. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80 (11A):26L-40L.
89. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart failure: An initial multicenter experience. J Pediatr 2001; 138:505-511.
90. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebocontrolled, randomized trials. Circulation 1998; 98:1184-1191.
91. Landy DC, Miller TL, Lipsitz SR, et al. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Cardiol 2012; 34:826-834. This study describes the additional risk from cranial irradiation exposure in childhood cancer survivors. Survivors exposed to cranial irradiation had significantly greater decreases in LV mass and dimension compared with those unexposed. Exposed survivors were also more likely to have low insulin-like growth factor-1 relative to normal values than unexposed, an observation possibly mediated by GH deficiency. These findings suggest that GH replacement therapy may help prevent the development of cardiotoxicity.
92. Lipshultz SE, Vlach SA, Lipsitz SR, et al. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics 2005; 115:1613-1622.
93. Landy DC, Lipsitz SR, Kurtz JM, et al. Dietary quality, caloric intake, and adiposity of childhood cancer survivors and their siblings: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivor Study. Nutr Cancer 2013; 65:547-555. This study found that dietary quality was only moderately adherent to current guidelines in childhood cancer survivors and their siblings. In survivors, decreased dietary quality was associated with higher body fat and receipt of cranial irradiation.
94. Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy: Implications for children. Paediatr Drugs 2005; 7:187-202.
95. Miller AM, Lopez-Mitnik G, Somarriba G, et al. Exercise capacity in long-term survivors of pediatric cancer: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Pediatr Blood Cancer 2013; 60:663-668. This study describes the lower exercise capacity (VO2 max) in childhood cancer survivors compared with their siblings. Risk factors for reduced VO2 max include older age and abnormal LV function and structure for men and women, higher percentage body fat for men, and methotrexate exposure for women. Survivors should be encouraged to exercise with close monitoring.
96. Landy DC, Miller TL, Lopez-Mitnik G, et al. Aggregating traditional cardiovascular risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study. Am Heart J 2012; 163:295-301.